Osteoporosis and Osteopathy Markers in Patients with Mastocytosis

Overview

Journal Turk J Haematol

Specialty Hematology

Date 2015 Mar 26

PMID 25805674

Citations 2

Authors

Nilufer Alpay Kanitez

Burak Erer

Oner Dogan

Nesimi Buyukbabani

Can Baykal

Dilsad Sindel

Refik Tanakol

Akif Selim Yavuz

Affiliations

Soon will be listed here.

Abstract

Objective: Osteoporosis, osteosclerosis, and lytic bone lesions have been observed in patients with systemic mastocytosis (SM). We examined bone mineral density (BMD) biochemical turnover markers and serum tryptase levels in SM, which is considered a rare disease.

Materials And Methods: Seventeen adult patients (5 females, 12 males; median age: 33 years, range: 20-64) with mastocytosis were included in this study. We investigated the value of quantitative ultrasound (QUS) of the calcaneus in the assessment of BMD in SM patients, as well as BMD of the lumbar spine (L1-L4), femoral neck, and distal radius using dual energy x-ray absorptiometry (DXA) and plasma tryptase levels, biochemical markers of bone turnover.

Results: At lumbar spine L1-L4, the femoral neck, and the distal radius or as calcaneus stiffness, 12 of 17 patients had T-scores of less than -1 at least at 1 site, reflecting osteopenia. Three of 17 patients had T-scores showing osteoporosis (T-score <-2.5). There was no relationship between DXA and bone lesion severity. We also found a significant positive correlation between tryptase levels and disease severity, as well as between disease severity and pyridinoline (p<0.01 by Spearman's test).

Conclusion: DXA and calcaneal QUS may not be appropriate techniques to assess bone involvement in SM patients because of the effects of osteosclerosis. This study further shows that the osteoclastic marker pyridinoline is helpful in patients with severe disease activity and sclerotic bone lesions to show bone demineralization.

Citing Articles

Hypertryptasemia and Mast Cell-Related Disorders in Severe Osteoporotic Patients.

Carosi G, Guabello G, Longhi M, Grifoni F, Passeri E, Corbetta S Mediators Inflamm. 2020; 2020:5785378.

PMID: 33144848 PMC: 7599415. DOI: 10.1155/2020/5785378.

Endocrine manifestations of systemic mastocytosis in bone.

Greene L, Asadipooya K, Freitas Corradi P, Akin C Rev Endocr Metab Disord. 2016; 17(3):419-431.

PMID: 27239674 DOI: 10.1007/s11154-016-9362-3.

References

Johansson C, Roupe G, Lindstedt G, Mellstrom D . Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing. 1996; 25(1):1-7. DOI: 10.1093/ageing/25.1.1. View

Chiappetta N, Gruber B . The role of mast cells in osteoporosis. Semin Arthritis Rheum. 2006; 36(1):32-6. DOI: 10.1016/j.semarthrit.2006.03.004. View

Inaoui R, Petit B, Jaccard A, Bertin P, Treves R . Aggressive systemic mastocytosis. Joint Bone Spine. 2003; 70(1):64-6. DOI: 10.1016/s1297-319x(02)00015-5. View

Fallon M, Whyte M, Teitelbaum S . Systemic mastocytosis associated with generalized osteopenia. Histopathological characterization of the skeletal lesion using undecalcified bone from two patients. Hum Pathol. 1981; 12(9):813-20. DOI: 10.1016/s0046-8177(81)80084-6. View

Prins S, Jorgensen H, Jorgensen L, Hassager C . The role of quantitative ultrasound in the assessment of bone: a review. Clin Physiol. 1998; 18(1):3-17. DOI: 10.1046/j.1365-2281.1998.00067.x. View

Brumsen C, Papapoulos S, Lentjes E, Kluin P, Hamdy N . A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men. Bone. 2002; 31(5):556-61. DOI: 10.1016/s8756-3282(02)00875-x. View

Nazarian A, Cory E, Muller R, Snyder B . Shortcomings of DXA to assess changes in bone tissue density and microstructure induced by metabolic bone diseases in rat models. Osteoporos Int. 2008; 20(1):123-32. DOI: 10.1007/s00198-008-0632-0. View

Lehmann T, Beyeler C, Lammle B, Hunziker T, Vock P, Olah A . Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol. 1996; 35(9):898-900. DOI: 10.1093/rheumatology/35.9.898. View

Lewiecki E, Borges J . Bone density testing in clinical practice. Arq Bras Endocrinol Metabol. 2006; 50(4):586-95. DOI: 10.1590/s0004-27302006000400004. View

10.

Valent P, Akin C, Sperr W, Escribano L, Arock M, Horny H . Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003; 27(7):635-41. DOI: 10.1016/s0145-2126(02)00168-6. View

11.

Sperr W, Fiegl M, Escribano L, Bellas C, Dirnhofer S, Semper H . Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol. 2002; 128(2):136-41. DOI: 10.1159/000059404. View

12.

Valent P, Akin C, Sperr W, Mayerhofer M, Fodinger M, Fritsche-Polanz R . Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2004; 46(1):35-48. DOI: 10.1080/10428190400010775. View

13.

Pusl T, Kenngott S, Bartl R, Baur A, Ludolph-Hauser D, Juengst D . A case of systemic mastocytosis associated with severe osteoporosis and pathologic fractures. Eur J Intern Med. 2005; 15(8):537-539. DOI: 10.1016/j.ejim.2004.11.003. View

14.

Valent P, Horny H, Escribano L, Longley B, Li C, Schwartz L . Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001; 25(7):603-25. DOI: 10.1016/s0145-2126(01)00038-8. View

15.

Danese R, Licata A . Ultrasound of the skeleton: review of its clinical applications and pitfalls. Curr Rheumatol Rep. 2001; 3(3):245-8. DOI: 10.1007/s11926-001-0025-2. View

16.

Nayak S, Olkin I, Liu H, Grabe M, Gould M, Allen I . Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis. Ann Intern Med. 2006; 144(11):832-41. DOI: 10.7326/0003-4819-144-11-200606060-00009. View

17.

Weide R, Ehlenz K, Lorenz W, Walthers E, Klausmann M, Pfluger K . Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol. 1996; 72(1):41-3. DOI: 10.1007/BF00663015. View

18.

Schwartz L, Sakai K, Bradford T, Ren S, Zweiman B, Worobec A . The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest. 1995; 96(6):2702-10. PMC: 185977. DOI: 10.1172/JCI118337. View

19.

van de Ven A, Erdtsieck R . Changes of bone mineral density, quantitative ultrasound parameters and markers of bone turnover during treatment of hyperthyroidism. Neth J Med. 2008; 66(10):428-32. View

20.

Khaw K, Reeve J, Luben R, Bingham S, Welch A, Wareham N . Prediction of total and hip fracture risk in men and women by quantitative ultrasound of the calcaneus: EPIC-Norfolk prospective population study. Lancet. 2004; 363(9404):197-202. DOI: 10.1016/S0140-6736(03)15325-1. View